NCT05335447已完成1 期
An Open-label Study in Healthy Male Subjects to Investigate the Metabolism and Excretion Pathways of GLPG3667 Following a Single Oral Dose of [14C]-GLPG3667 and to Determine the Absolute Bioavailability Relative to an Intravenous [14C]-GLPG3667 Microtracer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Galapagos NV
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Recovery of total radioactivity (TRA) excreted in urine expressed as a percentage of the administered dose (Ae%)
研究概览
简要总结
This is a study in healthy male volunteers to assess how a new test medicine is taken up and broken down by the body as well as its safety and tolerability.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 64 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male between 30 and 64 years of age (extremes included), on the date of signing the informed consent form (ICF).
- •A body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive.
- •Has a regular daily defecation pattern (i.e. 1 to 3 times per day).
- •Judged to be in good health by the investigator based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and fasting clinical laboratory safety tests. Neutrophil, lymphocyte, and platelet counts must be above the lower limit of normal range. Total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) must be within normal range. Other clinical laboratory safety test results must be within the normal ranges or test results that are outside the normal ranges need to be considered not clinically significant in the opinion of the investigator.
- •This list only contains the key inclusion criteria.
排除标准
- •Known hypersensitivity to GLPG3667 ingredients or history of a significant allergic reaction to GLPG3667 ingredients as determined by the investigator
- •Treatment with any medication (including over-the-counter (OTC) and/or prescription medication, COVID-19 vaccines, dietary supplements, nutraceuticals, vitamins and/or herbal supplements), except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) in the last 2 weeks or 5 half-lives of the drug, whichever is longer, prior to the first dosing.
- •Subject has participated in a [14C]-radiolabeled study within the past 12 months.
- •Radiation exposure, including that from the present study, excluding background radiation but including diagnostic X-rays and other medical exposures, exceeding 5 millisievert (mSv) in the last 12 months or 10 mSv in the last 5 years. Occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017 (UK, 2017), cannot participate in the study.
- •This list only contains the key exclusion criteria.
研究组 & 干预措施
Period 1 - Absolute Bioavailability
Experimental
干预措施: GLPG3667 capsule (Drug)
Period 1 - Absolute Bioavailability
Experimental
干预措施: [14C]-GLPG3667 solution for infusion (Drug)
Period 2 - Mass Balance
Experimental
干预措施: [14C]-GLPG3667 capsule (Drug)
结局指标
主要结局
Recovery of total radioactivity (TRA) excreted in urine expressed as a percentage of the administered dose (Ae%)
时间窗: From Day 1 until at least Day 8 in Period 2
Recovery of TRA excreted in feces expressed as a percentage of the administered dose (Af%)
时间窗: From Day 1 until at least Day 8 in Period 2
Recovery of TRA excreted in urine and feces expressed as a percentage of the administered dose (At%)
时间窗: From Day 1 until at least Day 8 in Period 2
Percentage of TRA in plasma and excreta for metabolites of interest
时间窗: From Day 1 until at least Day 8 in Period 2
Absolute oral bioavailability (F[percentage]) of GLPG3667
时间窗: From Day 1 until Day 4 in Period 1
次要结局
- Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuations.(From Day 1 through study completion, an average of 2 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205HealthyNCT04704739Galapagos NV12
已完成
1 期
Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970HealthyNCT04907149Galapagos NV6
已完成
1 期
An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male SubjectsMetabolism and EliminationNCT01975636Eisai Inc.113
已完成
1 期
RDEA3170 and Allopurinol Combination Study in Gout SubjectsGoutNCT02279641Ardea Biosciences, Inc.12
已完成
1 期
Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human BodySolid Tumors Harboring NTRK FusionNCT04275960Bayer24